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Preatment of Asymptomatic
dults With Elevated Coronary Calcium
cores With Atorvastatin, Vitamin C, and Vitamin E
he St. Francis Heart Study Randomized Clinical Trial
adon Arad, MD, FACC, Louise A. Spadaro, MD, FACC, Marguerite Roth, RN, David Newstein, DRPH,
lan D. Guerci, MD, FACC
oslyn, New York
OBJECTIVES We sought to determine whether lipid-lowering therapy and antioxidants retard the progression
of coronary calcification and prevent atherosclerotic cardiovascular disease (ASCVD) events.
BACKGROUND The electron beam computed tomography-derived coronary calcium score predicts coronary
disease events. Small, uncontrolled studies suggest that vigorous lipid-lowering therapy slows
progression of coronary calcification and prevents coronary artery disease events, but
controlled, scientific demonstration of these effects is lacking.
METHODS We conducted a double-blind, placebo-controlled randomized clinical trial of atorvastatin 20
mg daily, vitamin C 1 g daily, and vitamin E (alpha-tocopherol) 1,000 U daily, versus
matching placebos in 1,005 asymptomatic, apparently healthy men and women age 50 to 70
years with coronary calcium scores at or above the 80th percentile for age and gender. All
study participants also received aspirin 81 mg daily. Mean duration of treatment was 4.3 years.
RESULTS Treatment reduced total cholesterol by 26.5% to 30.4% (p 0.0001), low-density lipoprotein
cholesterol by 39.1% to 43.4% (p  0.0001), and triglycerides by 11.2% to 17.0% (p  0.02)
but had no effect (p  0.80) on progression of coronary calcium score (Agatston method).
Treatment also failed to significantly reduce the primary end point, a composite of all
ASCVD events (6.9% vs. 9.9%, p  0.08). Event rates were related to baseline calcium score
(pre-specified analysis) and may have been reduced in a subgroup of participants with baseline
calcium score 400 (8.7% vs. 15.0%, p  0.046 [not a pre-specified analysis]).
CONCLUSIONS Treatment with alpha-tocopherol, vitamin C, and low doses of atorvastatin (20 mg once
daily) did not affect the progression of coronary calcification. Treatment may have reduced
ASCVD events, especially in subjects with calcium scores 400, but these effects did not
achieve conventional levels of statistical significance. (J Am Coll Cardiol 2005;46:166–72)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.089© 2005 by the American College of Cardiology Foundation
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pn asymptomatic persons, the electron beam computed tomog-
aphy (CT)-derived coronary calcium score predicts coronary
rtery disease (CAD) events independently of standard CAD
isk factors (1–4). This observation suggests that criteria for
holesterol-lowering therapy should include the coronary cal-
ium score in addition to standard CAD risk factors.
See page 173
We therefore conducted a randomized, double-blind
linical trial of aspirin, atorvastatin, vitamin C, and vitamin
(alpha-tocopherol) versus aspirin and matching placebos
n apparently healthy men and women age 50 to 70 years
ith elevated coronary calcium scores. The primary purpose
f this study was to determine whether treatment with a
tatin and antioxidant vitamins can reduce the rate of
therosclerotic cardiovascular disease (ASCVD) events in
ersons identified at high risk by fast CT scanning of the
oronary arteries. A secondary objective of the study was to
From the Department of Research, St. Francis Hospital, Roslyn, New York.
upported by the St. Francis Hospital Foundation and by Pfizer, Inc.
Manuscript received December 12, 2004; revised manuscript received February 17,
005, accepted February 22, 2005.etermine the effect of treatment with a statin and antiox-
dant vitamins on progression of coronary calcification.
ETHODS
he methods have been previously published (5). To reca-
itulate briefly, men and women age 50 to 70 years were
onsidered eligible provided they had no history, symptoms
Rose questionnaire [6]), or signs of ASCVD. The latter
ncluded carotid bruits, diminished femoral or distal pulses,
nd either Q waves or poor precordial R-wave progression
n electrocardiograms.
Other exclusion criteria included indications for risk
actor modification or conditions that might interfere with
he conduct or conclusions of a randomized clinical trial.
he former consisted of insulin-dependent diabetes, triglyc-
rides 500 mg/dl, and in men, low-density lipoprotein
LDL) cholesterol 175 mg/dl (7). The upper limit for
holesterol in women, total cholesterol 300 mg/dl, was
hosen in the absence of any proof (circa January 1996) of
enefit of cholesterol-lowering therapy in women in a
etting of primary prevention and to conform to local
ractice patterns. Interfering conditions included weight
136 kg (the upper limit of the table), any disease likely to
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July 5, 2005:166–72 Treatment of Elevated Coronary Calcium Scoreause death within five years, current therapy with estrogens
r glucocorticoids, refusal to discontinue lipid-lowering
rugs, vitamin C or vitamin E, and uncontrolled hyperten-
ion, which was defined as systolic blood pressure180 mm
g or diastolic blood pressure 100 mm Hg. Low-density
ipoprotein cholesterol 90 mg/dl was also an exclusion
riterion. The lower limit for LDL cholesterol was chosen
ut of concern that local primary care physicians would
ecome alarmed by LDL cholesterol levels 60 mg/dl,
hich were known to be achievable with atorvastatin at the
ime of study design. Such alarm might have jeopardized
ompliance with assigned medications or even continued
articipation in the study.
Electron beam CT scanning was performed at enrollment
nd again at two and four years with reconstruction to a
6-cm field of view. Forty contiguous 3-mm slices were
canned during a single breath hold, beginning at the carina.
can time was 100 ms/slice, synchronized to 80% of the RR
nterval. At least two adjacent pixels with an attenuation
oefficient 130 Hounsfield units defined a calcified lesion,
nd coronary calcium scores were calculated using the
ethod of Agatston et al. (8).
Subjects with coronary calcium scores above the 80th
ercentile for age and gender, as defined by an internal
atabase comprising more than 5,000 asymptomatic per-
ons, were invited to participate in the randomized clinical
rial. The threshold calcium score was 26 in women age 50
o 51 years and increased by approximately 10% every two
ears up to a threshold score of 128 in women age 69 to 70
ears. In men, the threshold calcium score was 69 at age 50
o 51 years and increased by about 10% every two years up
o a threshold score of 368 in men age 69 to 70 years (5).
Treatment consisted of atorvastatin 20 mg daily, vitamin
1 g daily, and vitamin E (alpha tocopherol) 1,000 U daily
ersus matching placebos, administered in double-blind
ashion. In addition, at the insistence of the St. Francis
ospital Institutional Review Board, all participants were
iven 81 mg of aspirin daily. Study participants experiencing
onfatal coronary end points who met either Scandinavian
imvastatin Survival Study (4S) (9) or Cholesterol and
ecurrent Events (CARE) (10) criteria were placed on
pen-label atorvastatin 20 mg daily.
The primary hypothesis tested was that treatment with
torvastatin and vitamins C and E would reduce a compos-
te of all ASCVD events in a population defined as high risk
Abbreviations and Acronyms
ASCVD  atherosclerotic cardiovascular disease
CAD  coronary artery disease
CK-MB  creatine kinase-myocardial band
CT  computed tomography/tomographic
HDL  high-density lipoprotein
LDL  low-density lipoprotein
MI  myocardial infarctiony electron beam CT scanning of the coronary arteries dather than by conventional risk factor assessment. Events of
nterest, verified by an independent committee of current or
ormer coronary care unit directors at academic medical
enters, blinded to the coronary calcium score, included
oronary death, nonfatal myocardial infarction (MI), surgi-
al or percutaneous coronary revascularization procedures,
on-hemorrhagic stroke, and peripheral vascular (i.e., arte-
ial) surgery. For purposes of analysis, only the first event
xperienced by a patient was counted. Secondary end points
ncluded all coronary events, the sum of nonfatal MI and
oronary death, and all events occurring more than 90 days
fter randomization. The relationship of events to baseline
alcium score and standard risk factors was also a pre-
pecified analysis. A secondary hypothesis was that treat-
ent would reduce the rate of progression of the coronary
alcium score.
C-reactive protein was measured with a high-sensitivity
ssay, using latex immunonephelometry on a BN Prospec
nalyzer (Dade Behring, Newark, Delaware [11]).
This study was approved by the St. Francis Hospital
nstitutional Review Board and all participants gave in-
ormed consent.
andomization. The sample size of 944 was calculated on
he basis of a predicted event rate of 12% at four years in the
ontrol group, 80% power to detect a 50% reduction in
vents (two-sided test), and six interim analyses by the Data
nd Safety Monitoring Board, with O’Brien-Fleming
uidelines for each interim analysis. The slightly higher
ctual sample (n  1,005) was recruited in response to
ropouts during the recruitment phase, that is, most drop-
uts occurred in the first three months after randomization,
nd recruitment continued until 944 committed participants
ere enrolled. Participants were seen in follow-up at three-
onth intervals.
Randomization was stratified by gender, age (50 to 54
ears, 55 to 59 years, 60 to 64 years, and 65 to 70 years),
atio of LDL cholesterol to high-density lipoprotein (HDL)
holesterol (3.5 or 3.5), and the number of non-lipid
isk factors (0 to 2 or2). Data entry by either of two clerks
laced the patient into a cell and assigned a randomly
enerated number to that patient. Each number corre-
ponded to a treatment assignment. The same clerks also
ispensed study medications to study nurses in pre-
ackaged containers according to the treatment assignment
labels indicating container content, treatment or placebo,
ere removed by the clerks and filed). Other than the two
lerks and the statistician (D.N.), no study personnel had
ccess to or were made aware of treatment assignment.
tatistical analysis. Differences in proportions were tested
or significance using chi-square analyses. Differences in dis-
ributions of continuous variables were tested for significance
sing either independent sample t tests. In the case of the
oronary calcium scores, which were highly skewed, Wilcoxon
ank sum tests were used. Kaplan-Meier curves were used to
stimate the probability of sustaining a clinical event for a given
uration of follow-up, which enabled variable time of
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Treatment of Elevated Coronary Calcium Score July 5, 2005:166–72ollow-up (censoring) to be taken into account. Significance of
ifferences in the Kaplan-Meier curves by treatment group
ere assessed using log-rank tests. Multivariable proportional
azards regression was used to assess differences in time to
vent by treatment group while taking into account variable
ime of follow-up and adjusting for standard risk factors. All
ypothesis tests were conducted with an alpha level of 0.05 and
ere two tailed, and all end points were analyzed on the basis
f intention to treat.
In January of 2002, because of lower-than-expected event
ates and threatened dropout of large numbers of subjects
ho had been in the study for more than four years, we
ppealed to the Data and Safety Monitoring Board for
dvice on whether to continue the study. On the basis of
nformation available at that time, the Data and Safety
onitoring Board concluded that it was unlikely that the
nown event rate would yield a significant difference within
he next 6 to 12 months. Fearing substantial defections, we
lected to terminate the study rather than have a result
louded by large numbers of dropouts. Upon notifying all
tudy participants of our decision to end the study, we
ecame aware of additional events.
ole of the funding source. Neither the funding source
the St. Francis Hospital Foundation), nor Pfizer Inc.,
hich provided atorvastatin and matching placebo free of
harge, had any role in study design, the collection, analysis,
nd interpretation of data, or the preparation or submission
f this paper.
ESULTS
etween July 1996 and March 1999, 5,582 apparently
ealthy men and women age 50 to 70 years underwent
lectron beam CT scanning of the coronary arteries. Based
Table 1. Baseline Characteristics
Age (yrs)
Male (%)
Total cholesterol (mg/dl)
LDL cholesterol (mg/dl)
HDL cholesterol (mg/dl)
Triglycerides (mg/dl)
Hypertension (%)
Diabetes mellitus (%)
Current smoker (%)
Family history of premature CAD (%)
Body mass index 2
C-reactive protein (mg/l)
Median
25th, 75th percentiles
Calcium score
Mean
Median
25th, 75th percentiles
Normally distributed continuous variables are presented as m
To convert triglyceride levels to mmol/l, divide by 88.6.
CAD  coronary artery disease; HDL  high-density lin an internal database, 1,269 with coronary calcium scores at or above the 80th percentile for age and gender under-
ent physical examination, electrocardiography, and mea-
urement of risk factors. Of these, 177 were determined to
e ineligible, 87 withdrew before randomization, and 1,005
ere enrolled in the study. Although stratification of ran-
omization yielded an uneven number of participants in the
ctive treatment (n  490) and placebo (n  515) groups,
aseline characteristics were well matched (Table 1).
Of 185 dropouts, representing 18.4% of the study cohort,
0 occurred within 12 weeks of randomization. Thereafter,
he dropout rate was 3.1% per year. All dropouts took at
east some study medication, and all were included in data
nalysis.
Compliance, defined as consumption of at least 85% of
tudy medications, was assessed every three months and
veraged 85% for atorvastatin or its matching placebo,
8% for vitamins C and E or their matching placebos,
nd 79% for aspirin. Conversely, under the direction of
heir private physicians, 14% of subjects assigned to the
ontrol arm began taking a statin without an antecedent
SCVD event.
ffect of treatment on lipids. Treatment induced a 43%
eduction in LDL cholesterol (p  0.0001), a 17% reduc-
ion in triglycerides (p  0.0001), and a 30% reduction in
otal cholesterol (p  0.0001) at six weeks. Significant
hanges from baseline (p  0.0001) were maintained over
he course of the study. Differences in LDL cholesterol (p
.0001), triglycerides (0.02  p  0.0001), and total
holesterol (p  0.0001) between the treatment and control
roups also persisted throughout the study, despite the
rossover of a total of 21% of control arm subjects to
reatment with a statin.
ffect of treatment on ASCVD events (Fig. 1, Table 2). At
ment
490)
Control
(n  515) p Value
6 59  6 0.73
74 0.77
35 227  34 0.72
30 147  30 0.91
15 50  14 0.30
83 149  97 0.08
43 0.08
8 0.65
13 0.99
29 0.54
5.0 29.3  4.9 0.59
.99 2.10 0.99
4.24 0.96, 4.35
563 —
370 0.77
636 183, 671
SD. To convert cholesterol levels to mmol/l, divide by 38.7.
ein; LDL  low-density lipoprotein.Treat
(n 
59 
73
224 
146 
51 
136 
38
9
12
31
9.5 
1
0.97,
527
379
148,
ean mean of 4.3 years of follow-up, 34 treatment group
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July 5, 2005:166–72 Treatment of Elevated Coronary Calcium Scoreubjects (6.9%) and 51 control group subjects (9.9%) had
xperienced at least one ASCVD event (p  0.08). Treat-
ent reduced all CAD events by 28% (p  0.13), the sum
f nonfatal MI and coronary death by 44% (p  0.14), and
ll ASCVD events occurring more than 90 days after
nitiation of therapy by 33% (p  0.07).
ffect of treatment on progression of coronary calcifica-
ion (Table 3). Mean increase in calcium score at four years
as 331  421 U in the treatment group compared with
23  385 U in the control group (p  0.80).
eterminants of ASCVD events. Baseline coronary cal-
ium score (median [interquartile range]) was higher in
ubjects who sustained ASCVD events (581 [346, 1,148]),
han in those who did not (361 [175, 625], p  0.0001).
he coronary calcium score (mean  SD) also increased
ore from the baseline examination to the two-year exam-
nation in subjects who subsequently experienced ASCVD
vents than in those who remained event free (256 430 vs.
20  286, p  0.01).
In multivariate analysis, including standard CAD risk
actors, C-reactive protein, and baseline coronary calcium
core, only the calcium score was significantly associated
ith disease events (p  0.0001). Change in calcium score,
Figure 1. Kaplan-Meier survival cur
Table 2. Effect of Treatment on Clinical Even
Events Treat
Primary end point
All ASCVD* 34/490
Secondary end points
All coronary 31/490
Non-fatal MI/coronary death 9/490
All ASCVD after 90 days 30/486
*All atherosclerotic cardiovascular disease (ASCVD) events
coronary revascularization procedures, non-hemorrhagic stroke, and
points were pre-specified. A p value 0.05 notes statistical significhich was highly correlated with baseline calcium score, did
ot predict events after adjustment for these variables.
C-reactive protein did not predict events independently
f the calcium score (p  0.47), nor was there a significant
nteraction between C-reactive protein and calcium score on
reatment effect.
Among study participants with baseline calcium score
400 (47% of the study population), treatment reduced the
ncidence of all ASCVD events by 42% (20 of 229 [8.7%]
s. 36 of 240 [15.0%], p  0.046).
ISCUSSION
n this study of apparently healthy men and women age 50
o 70 years with elevated coronary calcium scores, treatment
ith aspirin 81 mg daily, atorvastatin 20 mg daily, vitamin
1,000 U daily, and vitamin C 1 g daily versus aspirin 81
g daily and matching placebos induced substantial and
ustained reductions in LDL cholesterol and triglycerides
ut failed to achieve conventional levels of statistical signif-
cance in the reduction of either all ASCVD events or CAD
vents. In contrast to earlier reports (12–14), treatment also
ailed to retard the progression of coronary calcification, a
r all atherosclerotic disease events.
Control p Value
) 51/515 (9.9%) 0.08
) 45/515 (8.7%) 0.13
) 17/515 (3.3%) 0.14
) 47/511 (9.2%) 0.07
des coronary death, non-fatal myocardial infarction (MI),ts
ment
(6.9%
(6.3%
(1.8%
(6.2%
inclu
peripheral revascularization procedures. All secondary end
ance for the primary end point.
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ean that current therapy cannot ameliorate the prognosis
f asymptomatic middle-aged persons with elevated coro-
ary calcium scores? We think not, but the answer to this
uestion requires consideration of several aspects of study
esign.
This study tested two cells of a two by two factorial:
torvastatin and antioxidant vitamins versus neither. Nei-
her monotherapy with atorvastatin nor antioxidants alone
as tested. This feature of study design was intentional and
epresented a balance between, on the one hand, the high
evel of interest in antioxidants at the time of the design of
he study (16) and, on the other hand, both the expectation
hat concurrent, large, randomized clinical trials would
efine the relative effects of statins and antioxidant vitamins
n intermediate- to high-risk populations and the practical
ealities of screening approximately 10,000 subjects in order
o obtain the 2,000 subjects with high coronary calcium
cores who would have been required for all four cells of a 2
2 factorial design. Although evidence in support of the
oxic effects of oxidized LDL cholesterol remains strong
17), alpha-tocopherol and ascorbic acid in doses similar to
hose given in the present study appear to have no effect on
he incidence of ASCVD events (18,19). Thus, the addition
f antioxidant vitamins to atorvastatin in this study probably
ad no effect on event rates.
A second relevant feature of study design was the defi-
ition of high risk. At the time that the study protocol was
esigned, we had evidence in symptomatic persons that for
ny given coronary calcium score, younger persons had more
oronary disease, defined angiographically, than older per-
Table 3. Effect of Treatment on Coronary Cal
Tr
Baseline
n
Mean
Median
25th, 75th percentiles 1
Year two
n
Mean
Median
25th, 75th percentiles 2
Change (year two minus baseline)
Absolute 13
Percent 3
Year four
n
Mean
Median
25th, 75th percentiles 33
Change (year four minus baseline)
Absolute 33
Percent 8
Because baseline calcium scores were not normally distributed
interquartile range [Wilcoxon rank sum test]), rather than m
the p value is based on comparison of the mean values andons (Guerci et al., unpublished data, 1995). Accordingly, ce established lower calcium score thresholds in younger
ersons than in older subjects.
This turned out to be an error, that is, age was not a
ignificant determinant of events. As a result of this error,
he study population contained substantial numbers of
ow-risk subjects, in whom treatment had little effect.
onversely, in just 469 subjects with calcium scores above
00, treatment reduced the event rate by 42%.
A third weakness of study design was the low dose of
torvastatin. This dose was selected out of concern over the
ossibility of toxicity associated with higher doses of ator-
astatin at a time when there was little published experience
ith the drug. In addition, we were concerned that study
articipants’ private physicians would become alarmed over
eclines in LDL cholesterol to levels below 60 mg/dl. Such
eclines, which were known to be readily achievable with
igher doses of atorvastatin even at the time of study design,
ight have jeopardized the blind or continued participation
n the study. As a consequence, LDL cholesterol was
educed only by 40%. Higher doses of atorvastatin would
ave further reduced LDL cholesterol and might also have
urther reduced the event rate (20–22).
Fourth, we had originally intended to make aspirin part
f the treatment regimen. However, our Institutional Re-
iew Board, aware of preliminary evidence of the high risk
ssociated with elevated coronary calcium scores (23), man-
ated administration of aspirin to both the treatment and
ontrol groups. This decision likely reduced the control
roup event rate (24), favoring the null hypothesis.
Additional support for the conclusion that the morbidity
nd mortality associated with a high coronary calcium score
Score
ent Control p Value
515
563 —
370 0.96
6 183, 671 —
431 —
723 —
505 —
0 251, 901
10 155  358 0.86
5 36  58 0.86
288
922 —
673 —
77 343, 1,138 —
21 323  385 0.80
9 73  93 0.76
lues are based on the distribution of calcium scores (median,
lues. Change in calcium scores was normally distributed and
espective variances.cium
eatm
490
528
379
84, 63
417
647
482
31, 82
7  3
8  7
281
846
623
5, 1,0
1  4
1  8
, p vaan be reduced significantly with statins and aspirin comes
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July 5, 2005:166–72 Treatment of Elevated Coronary Calcium Scorerom cross-sectional studies of survivors of first MI. Such
ersons, who are known to benefit from treatment with
tatins and aspirin (9,10,24), typically have coronary calcium
cores similar to or slightly higher than the median value of
75 observed in this study (1,25).
Last but not least, the 30% reduction in the primary end
oint is similar to the reduction of ASCVD events seen in
ther large randomized clinical trials of statins, a class of
rugs with unquestionable efficacy in this application. This
tudy had power of just 0.61 to detect a 30% reduction in
vents.
The failure of treatment to reduce the rate of progression
f the coronary calcium score was surprising, as a small
rospective study had indicated that reduction of LDL
holesterol to 100 mg/dl halted progression of coronary
alcification (12). Whether these conflicting results are due
o treatment with different statins (atorvastatin vs. cerivas-
atin), antioxidant vitamins, or other factors, is unknown.
ith different animal species, different diets, and different
rotocols, the experimental pathology literature also does
ot provide a clear answer to the question of stabilization of
alcification of atherosclerotic plaque during long-term
holesterol-lowering therapy (26–29).
In view of previous reports of the relationship between
hange in calcium score and acute MI (15), the failure of
hange in calcium score to predict ASCVD events seems to
e a function of power. Unable to distinguish coronary
alcium from coronary stents with certainty, and unwilling
o exclude some CAD events (i.e., percutaneous translumi-
al coronary angioplasty with stent), but not others from
nalysis, this analysis was restricted to subjects who experienced
first event after the year two follow-up scan (n  34).
The lack of interaction between baseline C-reactive
rotein and treatment was also surprising, given the pow-
rful effect noted in the Air Force/Texas Coronary Athero-
clerosis Prevention Study (AFCAPS/TEXCAPS), a study
ith almost seven times as many patient years of observation
30). Given the much larger patient population in the
FCAPS/TEXCAPS trial, the lack of association between
-reactive protein levels and treatment effect in the present
tudy seems most likely due to lack of power.
In summary, although atorvastatin, 20 mg daily, vitamin
1 g daily, and vitamin E 1,000 U daily failed to
ignificantly reduce ASCVD events in apparently healthy
iddle-aged men and women with elevated coronary cal-
ium scores, several lines of evidence indicate that this study
as underpowered and that the study population was
ndertreated, at least with respect to the dose of atorvasta-
in. Extrapolation from the results also suggests that a
ignificant difference would probably have been observed
ith a higher-risk population chosen exclusively on the basis
f a higher calcium score.
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